SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that it has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies. This trial is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies. The study will randomize a total of 40 healthy subjects between the ages of 18-55 to receive either an intramuscular injection or intravenous infusion of either ADM03820 or placebo at two clinical sites.
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that it has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies. This trial is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies. The study will randomize a total of 40 healthy subjects between the ages of 18-55 to receive either an intramuscular injection or intravenous infusion of either ADM03820 or placebo at two clinical sites.
ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that it has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies. This trial is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies. The study will randomize a total of 40 healthy subjects between the ages of 18-55 to receive either an intramuscular injection or intravenous infusion of either ADM03820 or placebo at two clinical sites.
Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD) has awarded the company with an agreement valued at $37 million. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.
Ology Bioservices, a biologics contract development and manufacturing organization based in Frederick, MD, announced on Aug. 26, 2020 that it has been contracted by the US Army Contracting Command at Aberdeen Proving Ground in Maryland to manage the production capacity of approximately 186,840,000 doses of COVID-19 vaccines and therapeutics.
ALACHUA, Fla.--(BUSINESS WIRE)--The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), to establish their proprietary Veroplex® cell platform for rapid response to emerging viral diseases.